Background The outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have
significantly improved through treatment intensification, yet Black representation in those …

Introduction Over the last decade, multiple clinical trials demonstrated improved survival
after chemotherapy for metastatic prostate cancer (mPCa). However, real‐world data …

In the last decade, there have been substantial improvements in the outcome of the
management of metastatic hormone-sensitive prostate cancer (mHSPC) following the …

Prostate cancer poses an ongoing problem in the western world accounting for significant
morbidity and mortality in the male population. Current therapy options are effective in …

Prostate-specific antigen (PSA) is the gold-standard marker to screen prostate cancer (PCa)
nowadays. Unfortunately, its lack of specificity and sensitivity makes the identification of …

Background Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has changed
drastically during the last years with the emergence of androgen receptor–targeted agents …

Background Few studies have comprehensively compared health-related quality of life
(HRQoL) between metastatic prostate cancer survivors, survivors with non-metastatic …

Transformation of primary prostate adenocarcinoma to squamous cell carcinoma after initial
treatment with chemotherapy and hormonal therapy is extremely rare and typically results in …

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer | Current
Oncology Reports Skip to main content SpringerLink Account Menu Find a journal Publish with …

Background We compared the effectiveness of currently available systemic therapies for
high-volume metastatic hormone-sensitive prostate cancer (mHSPC) and aimed to establish …